Avantor Stock Price, News & Analysis

Avantor, a global provider of critical products and services, is set to release its first quarter 2022 financial results after market close on April 28, 2022. The company will host a conference call on April 29, 2022, at 7:30 AM EDT to discuss the results. Investors can join via phone or access the live webcast through Avantor's investors section on its website. A replay of the call will be available until May 29, 2022.

Avantor (NYSE: AVTR), a leading global provider of mission-critical products, announced its participation in the KeyBanc Life Sciences and Medtech Investor Forum on March 22, 2022. Dr. Ger Brophy, Executive Vice President of Biopharma Production, will discuss the company’s business priorities in a fireside chat at approximately 2:15 p.m. EDT. A live webcast will be available on Avantor's website, with a replay accessible until April 22, 2022.

Avantor (NYSE: AVTR) is set to participate in the Barclays Global Healthcare Conference 2022 on March 15. Tom Szlosek, the Executive Vice President and CFO, will present in a fireside chat starting at 8:00 a.m. EDT. A live webcast of the event will be available on Avantor's investors section, with a replay accessible until April 15.

Avantor is a leading global provider in life sciences and advanced technologies, serving over 225,000 customer locations across more than 180 countries.

Avantor (NYSE: AVTR), a key player in mission-critical products for life sciences and advanced technologies, will participate in the 42nd Annual Cowen Healthcare Conference on March 7, 2022. CEO Michael Stubblefield is set to discuss the company's priorities in a fireside chat at 9:10 a.m. EST. The conversation will be available via a live webcast, with a replay accessible until April 7, 2022.

Avantor serves over 225,000 customer locations across more than 180 countries, playing a vital role in research and production within the biopharma and healthcare sectors.

Avantor, Inc. (NYSE: AVTR) announced the retirement of Board Chairman Rajiv Gupta effective at the end of his term, with no re-election for the upcoming May 12, 2022, annual stockholders meeting. Gupta has been instrumental in Avantor's growth since August 2010, emphasizing vision and value creation. The company plans to announce a new Board chair soon. Gupta expressed pride in Avantor's impact on stakeholders and confidence in its future success under a capable management team.

Avantor, a leading global provider of mission-critical products, reported robust financial results for Q4 2021 and the full year. Q4 net sales reached $1.91 billion, a 6.5% increase, with net income rising to $94 million. The company achieved over 11% organic growth in 2021 and expanded Adjusted EBITDA margin by nearly 190 basis points to 19.8% for the full year. Notably, adjusted EPS surged by approximately 58% to $1.41. The completion of the Masterflex acquisition solidified its fluid management solutions, showcasing commitment to long-term growth strategies.

Avantor has declared a quarterly cash dividend of $0.78 per share on its 6.250% Series A Mandatory Convertible Preferred Stock. This dividend will be paid on February 15, 2022 to shareholders of record as of February 1, 2022. The stock has a liquidation preference of $50. Avantor operates in the biopharma, healthcare, education, and advanced technology sectors, serving over 225,000 customer locations worldwide.

Avantor, Inc. (NYSE: AVTR) is set to release its financial results for Q4 and the full year of 2021 on February 3, 2022, after the market closes. Following this, a conference call will take place on February 4, 2022, at 7:30 a.m. ET to discuss the results. Interested participants can join the call by dialing specific numbers for domestic or international access. A live webcast will also be available on Avantor's investor website, with a replay open until March 3, 2022.

Argosy Healthcare Partners has appointed Greg Mayer to lead portfolio company operations, bringing a wealth of experience from his previous roles at Avantor and Bank of America. Argosy Healthcare Partners, a lower middle market private equity investor, aims to support founder-owned healthcare companies in scaling their businesses. With over $2.3 billion in assets under management, Argosy focuses on life sciences tools and pharmaceutical services, positioning itself to enhance growth opportunities in the healthcare sector.